Previous Article | Next Article 
Infection and Immunity, November 1999, p. 5848-5853, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Coadministration of Interleukin 12 Expression Vector with
Antigen 2 cDNA Enhances Induction of Protective Immunity against
Coccidioides immitis
Chengyong
Jiang,
D. Mitchell
Magee,* and
Rebecca A.
Cox
Department of Clinical Investigation, Texas
Center for Infectious Disease, San Antonio, Texas 78223
Received 29 April 1999/Returned for modification 8 June
1999/Accepted 30 July 1999
 |
ABSTRACT |
Interleukin 12 (IL-12) plays an important role in the induction of
protective immunity against cancer and infectious diseases. In this
study we asked whether IL-12 cDNA could increase the protective capacity of the antigen 2 (Ag2) gene vaccine in experimental
coccidioidomycosis. Coimmunization of BALB/c mice with a single-chain
IL-12 cDNA (p40-L-p35) and Ag2 cDNA, both subcloned into the pVR1012
plasmid, significantly enhanced protection against systemic challenge
with 2,500 arthroconidia, as evidenced by a greater-than-1.3-log-unit
reduction in the fungal load in the lungs and spleens compared to mice
receiving the pVR1012 vector alone, Ag2 cDNA alone, or IL-12 cDNA
alone. The enhanced protection was associated with increased gamma
interferon secretion; production of immunoglobulin G2a (IgG2a), IgG2b,
and IgG3 antibodies to Coccidioides immitis antigen; and
the influx of CD4+ and CD8+ T cells in lungs
and spleens. When challenged by the pulmonary route, mice covaccinated
with Ag2 cDNA and IL-12 cDNA were not protected at the lung level but
did show a significant reduction in the fungal load in their livers and
spleens compared to mice vaccinated with Ag2 cDNA or IL-12 cDNA alone.
These results suggest that IL-12 acts as a therapeutic adjuvant to
enhance Ag2 cDNA-induced protective immunity against experimental
coccidioidomycosis through the induction of Th1-associated immune responses.
 |
INTRODUCTION |
Interleukin 12 (IL-12), a
heterodimeric cytokine composed of a 40-kDa chain and a 35-kDa chain
(35), is produced by a variety of antigen-presenting cells,
including monocytes, macrophages, and B cells (24, 40, 41).
It displays a potent array of biological activities affecting natural
killer (NK) and T cells. These biological activities include the
ability to enhance the proliferation of T and NK cells; increase
cytolytic activities of T cells, NK cells, and macrophages; promote T
helper 1 (Th1) cell development; and induce production of
Th1-associated cytokines such as IL-2, tumor necrosis factor alpha, and
gamma interferon (IFN-
) (3, 9, 24, 30, 38-41, 45). The
induction of Th1-associated IFN-
has been recognized as one of the
most important functions of the IL-12-mediated cellular immune response
against tumors and infectious diseases (9, 41, 45, 46).
Coccidioidomycosis is a fungal disease caused by inhalation of
arthroconidia, the disarticulated mycelial phase of the dimorphic fungus Coccidioides immitis (37). This fungus is
endemic in the arid southwestern United States and Mexico in the
geographic area termed the lower Sonoran Life Zone, which also extends
into parts of Central and South America. The disease displays symptoms ranging from a mild flu-like syndrome to frank pneumonia. About 5% of
all cases result in severe, disseminated extrapulmonary disease.
Investigations with humans and experimentally infected animals have
documented that the severity of coccidioidomycosis directly correlates
with depressed cell-mediated immune responses, evidenced by decreased
skin test reactivity and the production of IFN-
and IL-2 in response
to coccidioidal antigens (4, 11, 14, 16, 28). It has been
also established that recovery from primary infection is accompanied by
strong cell-mediated immune responses to C. immitis antigens
and lifelong immunity against reinfection (13, 15, 37).
Our previous studies showed that IL-12 plays a central role in the
induction of host defenses against C. immitis
(29). Administration of recombinant IL-12 before and during
the course of the disease was shown to protect BALB/c mice against
challenge with C. immitis and to effect a shift in the Th1
response. Whereas control BALB/c mice demonstrated low levels of
IFN-
mRNA expression and high levels of IL-4 mRNA,
recombinant IL-12-treated mice exhibited high levels of IFN-
message
expression and low levels of IL-4 mRNA. More recently, we reported
that immunotherapy of BALB/c mice with J774 macrophages that had been
transduced with a plasmid expressing IL-12 cDNA ameliorated the course
of the disease (21). The decrease in disease severity was
associated with increased production of IFN-
. These results,
together with reports by others that IL-12 cDNA amplifies Th1 responses
to microbial vaccines (2, 3, 10, 19, 22, 36, 42-44),
document the feasibility of using IL-12 cDNA as an adjuvant for
vaccination against C. immitis.
Early studies with experimental animal models established that
vaccination with killed spherules induces protection against pulmonary challenge with a lethal dose of C. immitis
arthroconidia (27). Investigations by us (26) and
others (25, 33) showed that the protective component resided
in the cell walls and that cell wall extracts, enriched in antigen 2 (Ag2), induced protection against challenge with C. immitis.
We recently cloned the gene that encodes Ag2 (47, 48) and
showed that immunization of mice with the Ag2 gene induced protection
against intraperitoneal challenge with 2,500 arthroconidia of C. immitis (20). Our results were corroborated in a recent
study by Abuodeh et al. (1), who reported on the protective
capacity of a gene which encodes a proline-rich antigen. This gene was
previously shown to have a nucleotide sequence identical to that of Ag2
cDNA (17, 23).
The vaccine efficacy of Ag2 cDNA, coupled with the immunopotentiating
effects of IL-12, prompted us to determine if IL-12 cDNA would enhance
the induction of protective immunity in mice vaccinated with Ag2 cDNA.
Our results demonstrate that an IL-12-expressing plasmid has potent
adjuvant activity for enhancing Ag2 cDNA-induced protective immunity
and the induction of Th1 responses after systemic challenge with
C. immitis.
 |
MATERIALS AND METHODS |
Construction of recombinant plasmids.
The full-length
(194-nucleotide) Ag2 cDNA was subcloned into the XbaI site
of the eukaryotic expression vector plasmid pVR1012 as previously
reported (20).
Details of the procedure for the construction of a single chain of
murine IL-12 cDNA have been published earlier (21). Briefly, the cDNAs for the p40 and p35 subunits of IL-12 were amplified by PCR
and then linked with a synthetic linker by second-round PCR. The
1.66-kb PCR fragment was cloned into the pCR2.1 vector (InVitrogen, San
Diego, Calif.) and sequenced. To prepare the IL-12-expressing pVR1012
plasmid, the NotI-BamHI fragment of murine IL-12
was removed from pCR2.1-IL-12 cDNA and then subcloned into the pVR1012
plasmid. Previous experiments established that the recombinant
pVR1012-IL-12 plasmid expressed IL-12 mRNA, as measured by reverse
transcription-PCR, and was bioactive, as judged by the induction of
IFN-
by BALB/c spleen cells after incubation with the supernatant
from IL-12-transduced J774 macrophages (21).
To prepare plasmid DNA for immunization, Escherichia coli
XL-Blue cells were transformed with either pVR1012-Ag2, pVR1012-IL-12, or the pVR1012 plasmid alone and then cultured at 37°C for 16 h
in Luria broth supplemented with kanamycin (50 µg/ml). Plasmid DNA
was isolated by using an EndoFree plasmid purification kit (Qiagen,
Santa Clara, Calif.). The DNA was resuspended in USP saline (Baxter
Healthcare Corporation, Deerfield, Ill.) and stored at
20°C until used.
Immunization and challenge.
Five-week-old female BALB/c
(H-2d) mice were purchased from Jackson
Laboratory (Bar Harbor, Maine). The mice were maintained for at least 1 week before use.
DNA immunization was performed by injecting groups of mice
intramuscularly with 50 µg of pVR1012-Ag2 plus 5 µg of
pVR1012-IL-12. These doses were shown to be optimal in a series of
preliminary experiments. Comparative controls consisted of mice
vaccinated with 50 µg of pVR1012 DNA alone, 50 µg of pVR1012-Ag2
cDNA alone, or 5 µg of pVR1012-IL-12. Before each injection, the mice
were lightly anesthetized via inhalation of Metofane (Mallinckrodt Veterinary, Inc., Mundelein, Ill.). Injections were given in the tibialis anterior muscle in a site that had been treated with Nair
(Carter-Wallace, Inc., New York, N.Y.) 1 day before administration of
the first injection. A total of three immunizations were given at
weekly intervals in alternating sites on the left and right legs, and
the mice were challenged 2 weeks after the last immunization.
Challenge and assessment of disease severity.
Arthroconidia
were harvested from 4- to 8-week-old mycelium-phase cultures of
C. immitis CC, a recent isolate from a patient with
disseminated coccidioidomycosis. The arthroconidial suspensions were
passed over a nylon column to remove hyphal elements, and the cells
were enumerated by hemacytometer counts. Mice were infected by an
intraperitoneal injection with 2,500 arthroconidia suspended in 0.5 ml
of pyrogen-free saline or an intranasal instillation of 50 arthroconidia suspended in 30 µl of pyrogen-free saline. The
viability of the inocula was confirmed by plate counts on 1%
glucose-2% yeast extract agar.
Vaccine-induced protection was evaluated by determining the numbers of
C. immitis CFU in the lungs, spleens, and livers at 12 days postinfection as detailed earlier (20). At sacrifice, the organs were weighed, and the results obtained were expressed as
log10 CFU per gram of tissue.
Cytokine induction.
Spleens were harvested at day 12 after
challenge and processed as described above for single-cell suspensions
(20). The cultures were stimulated with the C. immitis cell wall extract C-ASWS, which contains native Ag2
(12); concanavalin A (ConA) (Sigma Chemical Co., St. Louis,
Mo.); or medium alone. After a 48-h incubation at 37°C under 5%
CO2, the supernatants were collected and stored at
20°C
until assayed.
Cytokine expression for IFN-
and IL-4 was assayed by two-site
sandwich enzyme-linked immunoassays (ELISA) as described previously (20, 21). All ELISA reagents were purchased from PharMingen, San Diego, Calif. Recombinant IFN-
and IL-4 proteins were used to
prepare standard curves.
Analysis of serum IgG isotypes.
Blood was collected from
mice on the day before challenge and 12 days after challenge. The sera
were harvested and stored at
20°C until assayed for immunoglobulin
G (IgG) antibody isotypes by ELISA. Wells on a 96-well microtiter plate
were coated with 100 ng of coccidioidin, prepared as a toluene-induced
lysate of young mycelia (34). Twofold serial dilutions of
mouse sera were added, and after a 1-h incubation at room temperature,
the plates were washed and incubated for 1 h with goat anti-mouse
IgG1, rabbit anti-mouse IgG2a, goat anti-mouse IgG2b, or goat
anti-mouse IgG3, each conjugated to alkaline phosphatase (Zymed, South
San Francisco, Calif.). The wells were washed, and the
p-nitrophenyl phosphate substrate (Sigma) was added to
obtain color development in 30 min. The reactions were read at 410 nm
on an MR 700 microplate reader (Dynatech Laboratories).
FACS analysis.
Spleens were gently teased to obtain
single-cell suspensions. The cells were suspended in cold Hanks'
balanced salt solution and treated with isotonic ammonium chloride to
lyse erythrocytes. The splenocytes were washed by centrifugation and
resuspended in Dulbecco's minimal essential medium (DMEM) (GIBCO,
Grand Island, N.Y.) supplemented with 10% fetal calf serum (FCS).
Fresh lung tissue was cut into small pieces with scissors and incubated
in DMEM containing 10% FCS, DNase I (100 U/ml; Sigma), and collagenase
(1 mg/ml; Sigma). After a 30-min incubation at 37°C under 5%
CO2, the digested samples were washed, and the erythrocytes were lysed with ammonium chloride. The lung cells were passed through a
nylon mesh to remove large tissue fragments, washed by centrifugation,
and resuspended in DMEM supplemented with 10% FCS.
A total of 106 splenocytes or lung cells were distributed
into a series of polypropylene tubes and washed three times with fluorescence-activated cell sorter (FACS) buffer (phosphate-buffered saline containing 0.1% FCS and 0.11% sodium azide). The cells were
incubated for 10 min with rat anti-mouse CD16 monoclonal antibody
(PharMingen) to block Fc receptors and then double stained with
saturating concentrations of phycoerythrin-conjugated hamster anti-mouse CD3 plus fluorescein isothiocyanate (FITC)-conjugated rat
anti-mouse CD45R/B220 monoclonal antibody, FITC-conjugated rat
anti-mouse CD4, or FITC-conjugated rat anti-mouse CD8, all from
PharMingen. After a 30-min incubation on ice, the cells were washed by
three centrifugations in FACS buffer, fixed by overnight incubation in
1% formalin, and then analyzed with a FACScan (Becton Dickinson,
Mountain View, Calif.).
Statistical analyses.
The data were analyzed by using the
Wilcoxon rank-sums test. Probability values of <0.05 were considered significant.
 |
RESULTS |
Enhanced efficacy of the Ag2 cDNA vaccine by the IL-12 expressing
plasmid.
To determine if IL-12 cDNA would increase the protective
capacity of the Ag2 gene vaccine, BALB/c mice were coinjected with pVR1012-Ag2 and pVR1012-IL-12 or, for comparative controls, pVR1012-Ag2 alone, pVR1012-IL-12 alone, or the pVR1012 plasmid. After three immunizations, the mice were challenged with 2,500 arthroconidia via an
intraperitoneal route and then sacrificed 12 days later and evaluated
for fungal CFU in the lungs and spleens. The results are shown in Fig.
1. Consistent with our earlier
investigation (20), mice vaccinated with Ag2 cDNA showed a
significant reduction in the fungal load in their lungs (P < 0.0001), livers (P < 0.0001), and spleens
(P < 0.0001) compared to mice vaccinated with the pVR1012 vector alone. Mice vaccinated with both IL-12 cDNA and Ag2 cDNA
were even more protected. The fungal loads in lungs, livers, and
spleens from mice given the combined vaccine were reduced by 54%
(P < 0.001), 35%, (P < 0.0001), and
19% (P > 0.05), respectively, compared to the number
of CFU in mice given Ag2 cDNA alone. Compared to the vector control
group, recipients of the combined vaccine showed a 68% reduction in
the CFU in their lungs (P < 0.0001), a 63% reduction
in their liver CFU (P < 0.0001), and a 44% reduction
in the fungal load in their spleens (P < 0.0001). Vaccination with pVR1012-IL-12 alone did not protect mice against systemic challenge.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Protection in BALB/c mice immunized with the pVR1012
vector, pVR1012-Ag2 alone, pVR1012-Ag2 plus pVR1012-IL-12, or
pVR1012-IL-12. Mice were challenged with 2,500 arthroconidia via an
intraperitoneal route and evaluated for fungal CFU in tissues 12 days
after challenge. Results depict means and standard errors obtained in
two experiments, each with 10 mice per group.
|
|
Since primary coccidioidomycosis is acquired via inhalation, we
examined protection in the vaccine groups after pulmonary challenge
with 50 arthroconidia. The results (Fig.
2) showed that mice vaccinated with
pVR1012-Ag2 plus pVR1012-IL-12 had significantly decreased
numbers of fungal CFU in their spleens and livers compared with mice
vaccinated with pVR1012-Ag2 alone (P < 0.0001),
pVR1012-IL-12 alone (P < 0.001), or the pVR1012 vector
alone (P < 0.0001). IL-12 cDNA alone also effected a
reduction in the CFU in spleens and livers of mice challenged by the
pulmonary route. This is an anomalous finding, considering that IL-12
cDNA alone did not induce protection against an intraperitoneal
challenge. None of the vaccine groups showed a decrease in the fungal
load in lungs.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
Protection in BALB/c mice immunized with the pVR1012
vector, pVR1012-Ag2 alone, pVR1012-Ag2 plus pVR1012-IL-12, or
pVR1012-IL-12. Mice were challenged with 50 arthroconidia via the
pulmonary route and evaluated for fungal CFU in tissues 12 days after
challenge. Results depict means and standard errors obtained in two
experiments, each with 10 mice per group.
|
|
Enhanced induction of IFN-
.
The foregoing results
established that the Ag2 gene vaccine combined with an IL-12-expressing
plasmid induced a significantly higher level of protection in mice than
either Ag2 cDNA or IL-12 cDNA alone. Since we and others have shown
that the induction of Th1-associated cellular responses is crucial to
the host defense against C. immitis (8, 15, 28),
spleen cells were collected from mice at 12 days postinfection and
assayed for the production of the Th1- and Th2-associated cytokines
IFN-
and IL-4, respectively.
Spleen cells from mice coimmunized with the Ag2- and IL-12-expressing
plasmids secreted IFN-
constitutively, as evidenced by the detection
of 600 pg of IFN-
in supernatants from the cells cultured in medium
alone (Table 1). Stimulation of the
splenocytes with C-ASWS resulted in a twofold increase in IFN-
production. Splenocytes from mice vaccinated with Ag2 cDNA alone also
secreted IFN-
in response to C-ASWS, but at a much lower level than
that obtained with spleen cells from mice coimmunized with Ag2
and IL-12. As expected, IFN-
secretion was not induced in
C-ASWS-stimulated spleen cells from mice immunized with the
pVR1012 vector alone or pVR1012-IL-12 alone. When stimulated with ConA,
spleen cells from all four groups of mice secreted IFN-
, with the
highest level noted in recipients of the combined Ag2-IL-12 vaccine.
In contrast to the increased production of the Th1-associated IFN-
response, spleen cells from Ag2-vaccinated mice and from mice
coinjected with the Ag2-IL-12 vaccine did not secrete the Th2 cytokine
IL-4 in response to stimulation with C-ASWS. The lack of IL-4
production does not indicate suppression of this Th2 response by IL-12,
since this cytokine was not produced by spleen cells from mice
immunized with the vector alone or IL-12 alone (Table 1).
Induction of Ag2-specific IgG antibody responses.
The patterns
of IgG antibody isotypes produced in response to immunization are
reliable indicators of the types of cytokines induced in vivo (5,
18, 30-32). IFN-
promotes the production of IgG2a, whereas
IL-4 promotes the production of IgG1. Although the patterns are less
clear with IgG2b and IgG3 isotypes, it is generally accepted that these
are associated with IFN-
production and are inhibited by IL-4
(5, 18).
To examine the humoral responses to the Ag2 gene vaccine and to
determine if the responses were modulated by coadministration of the
IL-12-expressing plasmid, sera were collected from mice on the day
before and 12 days after challenge and assayed for IgG isotype
antibodies to coccidioidin. As shown in Fig.
3, the combined Ag2-IL-12 vaccine
induced the production of IgG2a in the sera of mice before and, to a
greater level, after challenge with C. immitis. When
compared with the antibody response of mice given Ag2 cDNA alone, the
serum IgG2a levels in mice immunized with the combined
Ag2-plus-IL-12 vaccine was increased by fourfold. Serum
IgG2b and IgG3 antibodies were also induced in response to immunization
with Ag2 cDNA alone or with cDNA, and while IgG3 levels were slightly
reduced after challenge, IgG2b levels were increased. Although mice
immunized with Ag2 cDNA showed only a low level of IL-4 production
(Table 1), high levels of IgG1 antibodies were detected both before and
after challenge. Surprisingly, administration of IL-12 cDNA in
conjunction with Ag2 cDNA only slightly inhibited the production of
IgG1 antibodies.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 3.
IgG antibody isotypes levels in sera obtained from
BALB/c mice on the day before and 12 days after intraperitoneal
challenge with 2,500 arthroconidia, as assessed by ELISA with
coccidioidin as the target antigen. Results depict mean antibody levels
in assays of sera pooled from groups of 10 mice immunized with vector
( ), Ag2 ( ), Ag2 plus IL-12 ( ), or IL-12 ( ).
|
|
FACS analyses of lung and spleen lymphocytes.
To characterize
the cellular response to C. immitis in vaccinated mice,
spleens and lungs were obtained from mice 12 days after systemic
challenge and analyzed for lymphocyte populations by FACS. The results,
expressed as the percentage of lymphocytes identified as
CD3
B220+, CD3+ CD4+,
or CD3+ CD8+ by double staining with FITC- or
phycoerythrin-labeled antibodies against murine B cells and T-cell
subpopulations, are summarized in Table
2. The most striking difference in the
lymphocyte populations in the four mouse groups was the increase in the
percentage of CD3+ CD8+ T cells in the lungs
and spleens of mice coimmunized with Ag2- and IL-12-expressing plasmids
compared to those in mice immunized with the vector alone, pVR1012-Ag2
alone, or pVR1012-IL-12 alone. A slight increase in the percentages of
CD3+ CD4+ T cells in the lungs and spleens of
recipients of the combined vaccine was also noted. B220+ B
cells, on the other hand, were slightly increased in mice vaccinated with pVR1012-Ag2 alone or pVR1012-IL-12 alone compared to the percentages of B220+ B cells in mice vaccinated with the
plasmid alone and mice covaccinated with Ag2- and IL-12-expressing
plasmids.
 |
DISCUSSION |
This investigation established that coadministration of an
IL-12-expressing plasmid in the highly susceptible BALB/c mouse strain
enhances Ag2 cDNA vaccine-induced protection against systemic challenge
with C. immitis. The enhanced protective effect was accompanied by an increased production of the Th1-associated cytokine IFN-
, the production of anti-Ag2 IgG2a antibodies, and a cellular influx of CD4+ and CD8+ T cells. These
increased Th1-associated responses were accompanied, however, by only a
modest inhibition of the Th2-associated IgG1 production.
IFN-
has been recognized as one of the most important cellular
immune responses in coccidioidomycosis (6, 7, 15, 28). We
previously showed that treatment of the susceptible BALB/c mouse strain
with recombinant IFN-
ameliorated the course of the disease and,
using the reciprocal approach, that neutralization of endogenous
IFN-
in the resistant DBA/2 mouse strain led to disease progression
(28). The protective effects of IFN-
were shown to
reside, at least in part, in its ability to activate macrophages to an
anticoccidioidal level (15). In this investigation, we found
that IFN-
was produced constitutively only by splenocytes from mice
coimmunized with plasmids expressing Ag2 and IL-12 and that when
stimulated with ConA or C-ASWS, splenocytes from recipients of the
combined vaccine secreted more than fourfold-greater levels of IFN-
than did spleen cells from mice receiving either Ag2 cDNA or IL-12
cDNA. The increased production of IFN-
in response to the combined
vaccine versus either component alone establishes a synergistic effect
of Ag2 cDNA and IL-12 cDNA on the induction of this important
Th1-associated cytokine. Although our results suggest that IFN-
is
crucial to the protective effect of the Ag2-IL-12 vaccine, studies are
needed to show that treatment of mice with neutralizing anti-IFN-
significantly diminishes or abrogates protection.
Previous studies have shown that adoptive transfer of T cells, but not
serum, from immune mice protects recipients against challenge with
C. immitis (8). Both CD4+ and
CD8+ T cells were required for protection at the lung
level, as evidenced by the lack of adoptive transfer after depletion of
either subpopulation, whereas either T-cell subpopulation was able to
transfer protection in spleens (15). In this investigation,
analyses of lymphocyte populations in the lungs and spleens of mice
covaccinated with Ag2 cDNA and IL-12 cDNA revealed increases in both
CD4+ and CD8+ T cells. Whereas studies have
shown that CD4+ cells protect by secreting IFN-
and
other immunopotentiating cytokines (6-8, 15), the increase
in CD8+ cells in lungs or spleens from mice having
increased resistance to C. immitis raises the possibility
that the CD8+ cells may exert a cytotoxic effect on the fungus.
IL-12 has been reported to be an important enhancer of IgG2a antibodies
through the induction of IFN-
(5, 18, 30-32). Our
results showed that only the mice vaccinated with both the IL-12-expressing plasmid and Ag2 cDNA produced IgG2a, IgG2b, and IgG3
antibodies. These increased Th1-associated antibody responses were
accompanied, however, by only a modest inhibition of the Th2-associated
IgG1 production. This is an unexpected result given that IFN-
and
not IL-4 was produced by C-ASWS-stimulated spleen cells from mice
covaccinated with the Ag2- and IL-12-expressing plasmids. While it is
recognized that antibody isotype responses may vary during the course
of immunization and after challenge, owing to the changing dynamics of
Th1 and Th2 responses, the predominance of IgG1 both before and after
challenge is paradoxical and merits further study.
Although mice covaccinated with Ag2- and IL-12-expressing plasmids
showed a decreased fungal load in their lungs and spleens following
intraperitoneal challenge with C. immitis, the combined vaccine has limited effect on the fungal load in the lungs of mice
challenged by the pulmonary route. We believe that induction of
protective immunity at the lung level following pulmonary challenge may
be achieved by targeted delivery of the combined Ag2-IL-12 vaccine
directly to the lungs by using the adenovirus vector or DNA-liposome
complexes. Since the disease is acquired via the pulmonary route, the
induction of protection at the lung level remains a crucial goal for
the development of a vaccine for use in humans.
 |
ACKNOWLEDGMENTS |
This work was supported by grants AI32134 and AI21431 from the
National Institutes of Health and by a grant from the California Health
Care Foundation.
We gratefully acknowledge Teresa Quitugua, Melanie Woitaske, Isaac
Rosas, and Yiqiang Zhang for their expert assistance in the animal
studies. We also thank John Kalns at Brooks Aerospace Medical Center
for assistance in the FACS analyses.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Clinical Investigation, Texas Center for Infectious Disease, 2303 SE Military Dr., San Antonio, TX 78223. Phone: (210) 534-8857, ext. 2600. Fax: (210) 531-4550. E-mail:
mitch.magee{at}tdh.state.tx.us.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Abuodeh, R. O.,
L. F. Shubitz,
E. Siegel,
S. Snyder,
T. Peng,
K. I. Osborn,
E. Brummer,
D. A. Stevens, and J. N. Galgiani.
1999.
Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen.
Infect. Immun.
67:2935-2940[Abstract/Free Full Text].
|
| 2.
|
Afonso, L. C. C.,
T. M. Scharton,
L. Q. Vieira,
M. Wysocka,
G. Trinchieri, and P. Scott.
1994.
The adjuvant effect of interleukin 12 in a vaccine against Leishmania major.
Science
263:235-237[Abstract/Free Full Text].
|
| 3.
|
Ahlers, J. D.,
N. Dunlop,
D. W. Alling,
P. L. Nara, and J. A. Berzofsky.
1997.
Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. Granulocyte-macrophage colony-stimulating factor and TNF- synergize with IL-12 to enhance induction of cytotoxic T lymphocytes.
J. Immunol.
158:3947-3958[Abstract].
|
| 4.
|
Ampel, N. M.,
G. C. Bejarano,
S. D. Salas, and J. N. Galgiani.
1992.
In vitro assessment of cellular immunity in human coccidioidomycosis: relationship between dermal hypersensitivity, lymphocyte transformation, and lymphokine production by peripheral blood mononuclear cells from healthy adults.
J. Infect. Dis.
165:710-715[Medline].
|
| 5.
|
Arulanandam, B. P., and D. W. Metzer.
1999.
Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery.
Vaccine
17:252-260[Medline].
|
| 6.
|
Beaman, L.
1987.
Fungicidal activation of murine macrophages by recombinant gamma interferon.
Infect. Immun.
55:2951-2955[Abstract/Free Full Text].
|
| 7.
|
Beaman, L.,
E. Benjamini, and D. Pappagianis.
1983.
Activation of macrophages by lymphokines: enhancement of phagosome-lysosome fusion and killing of Coccidioides immitis.
Infect. Immun.
39:1201-1207[Abstract/Free Full Text].
|
| 8.
|
Beaman, L.,
D. Pappagianis, and E. Benjamini.
1977.
Significance of T cells in resistance to experimental murine coccidioidomycosis.
Infect. Immun.
17:580-585[Abstract/Free Full Text].
|
| 9.
|
Chan, S. H.,
B. Perussia,
J. W. Gupta,
M. Kobayashi,
M. Pospisil,
H. A. Young,
S. F. Wolf,
D. Yong,
S. C. Clark, and G. Trinchieri.
1991.
Induction of interferon production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers.
J. Exp. Med.
173:869-879[Abstract/Free Full Text].
|
| 10.
|
Chow, Y.-H.,
B.-L. Chiang,
Y.-L. Lee,
W.-K. Chi,
W.-C. Lin,
Y.-T. Chen, and M.-H. Tao.
1998.
Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.
J. Immunol.
160:1320-1329[Abstract/Free Full Text].
|
| 11.
|
Corry, D. B.,
N. M. Ampel,
L. Christian,
R. M. Locksley, and J. N. Galgiani.
1996.
Cytokine production by peripheral blood mononuclear cells in human coccidioidomycosis.
J. Infect. Dis.
174:440-443[Medline].
|
| 12.
|
Cox, R. A., and L. A. Britt.
1985.
Antigenic heterogeneity of an alkali-soluble, water-soluble cell wall extract of Coccidioides immitis.
Infect. Immun.
50:365-369[Abstract/Free Full Text].
|
| 13.
|
Cox, R. A.,
E. Brumer, and G. Lecara.
1977.
In vitro lymphocyte responses of coccidioidin skin-test positive and -negative persons to coccidioidin, spherulin, and a Coccidioides immitis cell wall antigen.
Infect. Immun.
15:751-755[Abstract/Free Full Text].
|
| 14.
|
Cox, R. A.,
W. Kennell,
L. Boncyk, and J. W. Murphy.
1988.
Induction and expression of cell-mediated immune responses in inbred mice infected with Coccidioides immitis.
Infect. Immun.
56:13-17[Abstract/Free Full Text].
|
| 15.
|
Cox, R. A., and D. M. Magee.
1998.
Protective immunity in coccidioidomycosis.
Res. Immunology
149:417-428[Medline].
|
| 16.
|
Cox, R. A., and J. R. Vivas.
1977.
Spectrum of in vivo and in vitro immune responses in coccidioidomycosis.
Cell. Immunol.
31:130-141[Medline].
|
| 17.
|
Dugger, K. O.,
K. M. Willareal,
A. Ngyuen,
C. R. Zimmermann,
J. H. Law, and J. N. Galgiani.
1996.
Cloning and sequence analysis of the cDNA for a protein from Coccidioides immitis with immunogenic potential.
Biochem. Biophys. Res. Commun.
218:485-489[Medline].
|
| 18.
|
Guery, J.-C.,
F. Galbiati,
S. Smiroldo, and L. Adorini.
1996.
Normal and 2-microglobulin-deficient BALB/c mice.
J. Exp. Med.
183:485-497[Abstract/Free Full Text].
|
| 19.
|
Irvine, K. R.,
J. B. Rao,
S. A. Rosenberg, and N. P. Restifo.
1996.
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
J. Immunol.
156:238-245[Abstract].
|
| 20.
|
Jiang, C.,
D. M. Magee,
T. N. Quitugua, and R. A. Cox.
1999.
Genetic vaccination against Coccidioides immitis: comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA.
Infect. Immun.
67:630-635[Abstract/Free Full Text].
|
| 21.
|
Jiang, C.,
D. M. Magee, and R. A. Cox.
1999.
Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental coccidioidomycosis.
Infect. Immun.
67:2996-3001[Abstract/Free Full Text].
|
| 22.
|
Kim, J. J.,
V. Ayyavoo,
M. L. Bagarazzi,
M. A. Chattergoon,
K. Dang,
B. Wang,
J. D. Boyer, and D. B. Weiner.
1997.
In vivo engineering of a cellular immune response by co-administration of IL-12 expression vector with DNA immunogen.
J. Immunol.
158:816-826[Abstract].
|
| 23.
|
Kirkland, T. N.,
F. Finley,
K. I. Orsborn, and J. N. Galgiani.
1998.
Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice.
Infect. Immun.
66:3519-3522[Abstract/Free Full Text].
|
| 24.
|
Kobayashi, M.,
L. Fitz,
M. Ryan,
R. M. Hewick,
S. C. Clark,
S. Chan,
R. Loudon,
F. Sherman,
B. Perussia, and G. Trinchiera.
1989.
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes.
J. Exp. Med.
170:827-845[Abstract/Free Full Text].
|
| 25.
|
Kong, Y. M.,
H. B. Levine, and C. E. Smith.
1963.
Immunogenic properties of nondisrupted and disrupted spherules of Coccidioides immitis in mice.
Sabouraudia
2:131-142[Medline].
|
| 26.
|
Lecara, G.,
R. A. Cox, and R. B. Simpson.
1983.
Coccidioides immitis vaccine: potential of an alkali-soluble, water-soluble cell wall antigen.
Infect. Immun.
39:473-475[Abstract/Free Full Text].
|
| 27.
|
Levine, H. B.,
J. M. Cobb, and C. E. Smith.
1961.
Immunogenicity of spherule-endospore vaccines of Coccidioides immitis for mice.
J. Immunol.
87:218-227.
|
| 28.
|
Magee, D. M., and R. A. Cox.
1995.
Roles of gamma interferon and interleukin-4 in genetically determined resistance to Coccidioides immitis.
Infect. Immun.
63:3514-3518[Abstract].
|
| 29.
|
Magee, D. M., and R. A. Cox.
1996.
Interleukin-12 regulation of host defenses against Coccidioides immitis.
Infect. Immun.
64:3609-3613[Abstract].
|
| 30.
|
McKnight, A. J.,
G. J. Zimmer,
I. Fogelman,
S. F. Wolf, and A. K. Abbas.
1994.
Effects of IL-12 on helper T cell-dependent immune responses in vivo.
J. Immunol.
152:2172-2179[Abstract].
|
| 31.
|
Metzger, D. W.,
R. M. McNutt,
J. T. Collins,
J. M. Buchanan,
V. H. V. Cleve, and W. A. Dunick.
1997.
Interleukin-12 acts as an adjuvant for humoral immunity through interferon- -dependent and -independent mechanisms.
Eur. J. Immunol.
27:1958-1965[Medline].
|
| 32.
|
Mosmann, T. R., and R. L. Coffman.
1989.
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
Annu. Rev. Immunol.
7:145-173[Medline].
|
| 33.
|
Pappagianis, D.,
R. Hector,
H. B. Levine, and M. S. Collins.
1979.
Immunization of mice against coccidioidomycosis with a subcellular vaccine.
Infect. Immun.
25:440-445[Abstract/Free Full Text].
|
| 34.
|
Pappagianis, D.,
C. E. Smith,
G. S. Kobayashi, and M. T. Saito.
1961.
Studies of antigens from young mycelia of Coccidioides immitis.
J. Infect. Dis.
108:35-44[Medline].
|
| 35.
|
Schoenhaut, D. S.,
A. O. Chua,
A. G. Wolitzky,
M. Phyllis,
P. M. Quinn,
C. M. Dwyer,
W. McComas,
P. C. Familletti,
M. K. Gately, and U. Gubler.
1992.
Cloning and expression of murine IL-12.
J. Immunol.
148:3433-3440[Abstract].
|
| 36.
|
Sin, J.-I.,
J. J. Kim,
R. L. Arnold,
K. E. Shroff,
D. McCallus,
C. Pachuk,
S. P. McElhiney,
M. W. Wolf,
S. J. Pompa-de Bruin,
T. J. Higgins,
R. B. Ciccarelli, and D. B. Weiner.
1999.
IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.
J. Immunol.
162:2912-2921[Abstract/Free Full Text].
|
| 37.
|
Stevens, D. A.
1995.
Current concepts: coccidioidomycosis.
N. Engl. J. Med.
332:1077-1082[Free Full Text].
|
| 38.
|
Sypek, J. P.,
C. L. Chung,
S. E. H. Mayor,
J. M. Subramanyam,
S. J. Goldman,
D. S. Sieburth,
S. F. Wolf, and R. G. Schaub.
1993.
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.
J. Exp. Med.
177:1797-1802[Abstract/Free Full Text].
|
| 39.
|
Tahara, H.,
L. Zitvogel,
W. J. Storkus,
H. J. Zeh III,
T. G. McKinney,
R. D. Schreiber,
U. Gubler,
P. D. Robbins, and M. T. Lotze.
1995.
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.
J. Immunol.
154:6466-6474[Abstract].
|
| 40.
|
Trinchieri, G.
1994.
Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.
Blood
84:4008-4027[Free Full Text].
|
| 41.
|
Trinchieri, G.
1995.
Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.
Annu. Rev. Immunol.
152:1883-1887.
|
| 42.
|
Tsuji, T.,
K. Hamajima,
J. Fukushima,
K.-Q. Xin,
N. Ishii,
I. Aoki,
Y. Ishigatsubo,
K. Tani,
S. Kawamoto,
Y. Nitta,
J.-I. Miyazaki,
W. C. Koff,
T. Okubo, and K. Okuda.
1997.
Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12.
J. Immunol.
158:4008-4013[Abstract].
|
| 43.
|
Wynn, T. A.,
A. W. Cheever,
D. Jankovic,
R. W. Poindexter,
P. Caspar,
F. A. Lewis, and A. Sher.
1995.
An IL-12 based vaccination method for preventing fibrosis induced by schistosome infection.
Nature
376:594-596[Medline].
|
| 44.
|
Wynn, T. A.,
D. Jankovic,
S. Hieny,
A. W. Cheever, and A. Sher.
1995.
IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production, and tissue eosinophilia.
J. Immunol.
154:4701-4709[Abstract].
|
| 45.
|
Zatloukal, K.,
A. Schneeberger,
M. Berger,
W. Schmidt,
F. Koszik,
R. Kutil,
M. Cotton,
E. Wagner,
M. Buschle,
G. Maass,
E. Payer,
G. Stingl, and M. L. Birnstiel.
1995.
Elicitation of a systemic and protective anti-melanoma immune response by an IL-12 based vaccine.
J. Immunol.
154:3406-3419[Abstract].
|
| 46.
|
Zhou, P.,
M. C. Sieve,
J. Bennett,
K. J. Kwon-Chung,
R. P. Tewari,
R. T. Gazzinelli,
A. Sher, and R. A. Seder.
1995.
IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN- .
J. Immunol.
155:785-795[Abstract].
|
| 47.
|
Zhu, Y.,
C. Yang,
D. M. Magee, and R. A. Cox.
1996.
Coccidioides immitis antigen 2: analysis of gene and protein.
Gene
181:121-125[Medline].
|
| 48.
|
Zhu, Y.,
C. Yang,
D. M. Magee, and R. A. Cox.
1996.
Molecular cloning and characterization of Coccidioides immitis antigen 2 cDNA.
Infect. Immun.
64:2695-2699[Abstract].
|
Infection and Immunity, November 1999, p. 5848-5853, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
de Bastos Ascenco Soares, R., Gomez, F. J., de Almeida Soares, C. M., Deepe, G. S. Jr.
(2008). Vaccination with Heat Shock Protein 60 Induces a Protective Immune Response against Experimental Paracoccidioides brasiliensis Pulmonary Infection. Infect. Immun.
76: 4214-4221
[Abstract]
[Full Text]
-
Luo, D., Ni, B., Li, P., Shi, W., Zhang, S., Han, Y., Mao, L., He, Y., Wu, Y., Wang, X.
(2006). Protective Immunity Elicited by a Divalent DNA Vaccine Encoding Both the L7/L12 and Omp16 Genes of Brucella abortus in BALB/c Mice.. Infect. Immun.
74: 2734-2741
[Abstract]
[Full Text]
-
Orsborn, K. I., Shubitz, L. F., Peng, T., Kellner, E. M., Orbach, M. J., Haynes, P. A., Galgiani, J. N.
(2006). Protein Expression Profiling of Coccidioides posadasii by Two-Dimensional Differential In-Gel Electrophoresis and Evaluation of a Newly Recognized Peroxisomal Matrix Protein as a Recombinant Vaccine Candidate. Infect. Immun.
74: 1865-1872
[Abstract]
[Full Text]
-
Cox, R. A., Magee, D. M.
(2004). Coccidioidomycosis: Host Response and Vaccine Development. Clin. Microbiol. Rev.
17: 804-839
[Abstract]
[Full Text]
-
Onate, A. A., Cespedes, S., Cabrera, A., Rivers, R., Gonzalez, A., Munoz, C., Folch, H., Andrews, E.
(2003). A DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus Induces Protective Immunity in BALB/c Mice. Infect. Immun.
71: 4857-4861
[Abstract]
[Full Text]
-
Garg, N., Tarleton, R. L.
(2002). Genetic Immunization Elicits Antigen-Specific Protective Immune Responses and Decreases Disease Severity in Trypanosoma cruzi Infection. Infect. Immun.
70: 5547-5555
[Abstract]
[Full Text]
-
Peng, T., Shubitz, L., Simons, J., Perrill, R., Orsborn, K. I., Galgiani, J. N.
(2002). Localization within a Proline-Rich Antigen (Ag2/PRA) of Protective Antigenicity against Infection with Coccidioides immitis in Mice. Infect. Immun.
70: 3330-3335
[Abstract]
[Full Text]
-
Jiang, C., Magee, D. M., Ivey, F. D., Cox, R. A.
(2002). Role of Signal Sequence in Vaccine-Induced Protection against Experimental Coccidioidomycosis. Infect. Immun.
70: 3539-3545
[Abstract]
[Full Text]
-
Shubitz, L., Peng, T., Perrill, R., Simons, J., Orsborn, K., Galgiani, J. N
(2002). Protection of Mice against Coccidioides immitis Intranasal Infection by Vaccination with Recombinant Antigen 2/PRA. Infect. Immun.
70: 3287-3289
[Abstract]
[Full Text]
-
Palendira, U., Kamath, A. T., Feng, C. G., Martin, E., Chaplin, P. J., Triccas, J. A., Britton, W. J.
(2002). Coexpression of Interleukin-12 Chains by a Self-Splicing Vector Increases the Protective Cellular Immune Response of DNA and Mycobacterium bovis BCG Vaccines against Mycobacterium tuberculosis. Infect. Immun.
70: 1949-1956
[Abstract]
[Full Text]
-
Leutenegger, C. M., Boretti, F. S., Mislin, C. N., Flynn, J. N., Schroff, M., Habel, A., Junghans, C., Koenig-Merediz, S. A., Sigrist, B., Aubert, A., Pedersen, N. C., Wittig, B., Lutz, H.
(2000). Immunization of Cats against Feline Immunodeficiency Virus (FIV) Infection by Using Minimalistic Immunogenic Defined Gene Expression Vector Vaccines Expressing FIV gp140 Alone or with Feline Interleukin-12 (IL-12), IL-16, or a CpG Motif. J. Virol.
74: 10447-10457
[Abstract]
[Full Text]